Based on the Merrimack Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Merrimack Pharmaceuticals Inc is not available over the next 12 months. Merrimack Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Merrimack Pharmaceuticals Inc is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Merrimack Pharmaceuticals Inc’s stock price was USD 14.73. Merrimack Pharmaceuticals Inc’s stock price has changed by +0.34% over the past week, +0.00% over the past month and +21.74% over the last year.
No recent analyst target price found for Merrimack Pharmaceuticals Inc
No recent average analyst rating found for Merrimack Pharmaceuticals Inc
Company Overview Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Read Less
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions About Merrimack Pharmaceuticals Inc (MACK) Stock
Stock Target Advisor's fundamental analysis for Merrimack Pharmaceuticals Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on MACK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on MACK's stock to indicate what its average analyst target is.
MACK stock's Price/Earning ratio is 65.10.
Our analysis grades MACK stock's Price / Earning ratio at F. This means that MACK stock's Price/Earning ratio is above 87% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MACK may be a overvalued for its sector.
The last closing price of MACK's stock was USD 14.73.
The most recent market capitalization for MACK is USD 0.21B.
Unfortunately we do not have enough analyst data on MACK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Merrimack Pharmaceuticals Inc's stock.
As per our most recent records Merrimack Pharmaceuticals Inc has 0 Employees.
Merrimack Pharmaceuticals Inc's registered address is One Broadway, Cambridge, MA, United States, 02142.
You can get more information about it from Merrimack Pharmaceuticals Inc's website at https://www.merrimack.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MACK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
